| Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer T André, C Boni, L Mounedji-Boudiaf, M Navarro, J Tabernero, T Hickish, ... New England Journal of Medicine 350 (23), 2343-2351, 2004 | 4621 | 2004 |
| FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study C Tournigand, T André, E Achille, G Lledo, M Flesh, D Mery-Mignard, ... Journal of Clinical Oncology 22 (2), 229-237, 2004 | 3985 | 2004 |
| Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial T André, C Boni, M Navarro, J Tabernero, T Hickish, C Topham, A Bonetti, ... Journal of Clinical Oncology 27 (19), 3109-3116, 2009 | 2818 | 2009 |
| Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study MJ Overman, R McDermott, JL Leach, S Lonardi, HJ Lenz, MA Morse, ... The lancet oncology 18 (9), 1182-1191, 2017 | 2746 | 2017 |
| Pembrolizumab in microsatellite-instability–high advanced colorectal cancer T André, KK Shiu, TW Kim, BV Jensen, LH Jensen, C Punt, D Smith, ... New England Journal of Medicine 383 (23), 2207-2218, 2020 | 2238 | 2020 |
| Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair–deficient/microsatellite instability–high metastatic colorectal cancer MJ Overman, S Lonardi, KYM Wong, HJ Lenz, F Gelsomino, M Aglietta, ... Journal of clinical oncology 36 (8), 773-779, 2018 | 2042 | 2018 |
| KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab A Lievre, JB Bachet, V Boige, A Cayre, D Le Corre, E Buc, M Ychou, ... Journal of clinical oncology 26 (3), 374-379, 2008 | 1968 | 2008 |
| Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial J Bennouna, J Sastre, D Arnold, P Österlund, R Greil, E Van Cutsem, ... The lancet oncology 14 (1), 29-37, 2013 | 1385 | 2013 |
| Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial C Louvet, R Labianca, P Hammel, G Lledo, MG Zampino, T André, ... Journal of Clinical Oncology 23 (15), 3509-3516, 2005 | 1273 | 2005 |
| Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib … P Hammel, F Huguet, JL van Laethem, D Goldstein, B Glimelius, P Artru, ... Jama 315 (17), 1844-1853, 2016 | 1101 | 2016 |
| OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer—a GERCOR study C Tournigand, A Cervantes, A Figer, G Lledo, M Flesch, M Buyse, ... Journal of clinical oncology 24 (3), 394-400, 2006 | 1095 | 2006 |
| Duration of adjuvant chemotherapy for stage III colon cancer A Grothey, AF Sobrero, AF Shields, T Yoshino, J Paul, J Taieb, ... New England Journal of Medicine 378 (13), 1177-1188, 2018 | 1008 | 2018 |
| Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer: KEYNOTE-164 DT Le, TW Kim, E Van Cutsem, R Geva, D Jäger, H Hara, M Burge, ... Journal of clinical oncology 38 (1), 11-19, 2020 | 890 | 2020 |
| Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials DJ Sargent, HS Wieand, DG Haller, R Gray, JK Benedetti, M Buyse, ... Journal of Clinical Oncology 23 (34), 8664-8670, 2005 | 797 | 2005 |
| Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials D Sargent, A Sobrero, A Grothey, MJ O'Connell, M Buyse, T Andre, ... Journal of Clinical Oncology 27 (6), 872-877, 2009 | 757 | 2009 |
| Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and … T André, A De Gramont, D Vernerey, B Chibaudel, F Bonnetain, ... Journal of Clinical Oncology 33 (35), 4176-4187, 2015 | 753 | 2015 |
| Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial A de Gramont, E Van Cutsem, HJ Schmoll, J Tabernero, S Clarke, ... The lancet oncology 13 (12), 1225-1233, 2012 | 652 | 2012 |
| Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies F Huguet, T André, P Hammel, P Artru, J Balosso, F Selle, ... Journal of Clinical Oncology 25 (3), 326-331, 2007 | 647 | 2007 |
| Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3 E Van Cutsem, R Labianca, G Bodoky, C Barone, E Aranda, B Nordlinger, ... Journal of Clinical Oncology 27 (19), 3117-3125, 2009 | 613 | 2009 |
| Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients C Louvet, T Andre, JM Tigaud, E Gamelin, JY Douillard, R Brunet, ... Journal of Clinical Oncology 20 (23), 4543-4548, 2002 | 596 | 2002 |
Benoist ChibaudelService d'Oncologie Médicale, Institut Hospitalier Franco-Britannique - Levallois-Perret, FranceEmail verificata su ihfb.org